Cellartis cardiomyocytes derived from human induced pluripotent stem cells
Cellartis cardiomyocytes* are a highly homogeneous population of cardiomyocytes derived from human induced pluripotent stem (iPS) cells (ChiPSC22). The iPS cells have been differentiated into spontaneously beating cardiomyocytes in vitro. These cells have been dissociated into a single-cell suspension and frozen in vials. The Cellartis Cardiomyocytes (from ChiPSC22) Kit contains one vial of cardiomyocytes (>3 x 106 viable cells), one bottle of Cellartis CM Thawing Base, and one bottle of Cellartis CM Culture Base.
*Cellartis cardiomyocytes are no longer available in the US.
Overview
-
Electrophysiological profile highly resembling adult human primary cardiomyocytes
-
Respond as expected to cardiac stimuli
-
Derived with a robust, efficient cardiac differentiation protocol, without genetic engineering or selection
-
Cells are provided with basal medium for thawing and culture
More Information
Applications
-
Safety pharmacology
-
Cardiotoxicity testing
-
Discovery of novel cardiac drug targets
-
Phenotypic screening
-
High-content analysis (HCA)
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.